Bristol, United Kingdom
FluoretiQ Limited, established in 2017, is a UK-based company making strides in the Health Care and Medical Devices industries. With the slogan, "Make the first Prescription, the right Prescription," FluoretiQ is revolutionizing point-of-care diagnostics by ensuring the initial prescription is both accurate and effective.
The company's innovations include NANOPLEX®, a rapid diagnostic test that identifies and quantifies infections in just five minutes. Coupled with SCFI™, a real-time antibiotic susceptibility test that outlines effective treatment options within 30 minutes, FluoretiQ addresses critical healthcare needs by optimizing antibiotic use.
Having secured a £1.10M Seed Round investment in February 2022 from investors including Deepbridge Capital, MAINStream, Leonid Shapiro, Oxford Investment Opportunity Network, and SAIC, FluoretiQ is poised for significant impact in the clinical diagnostics market, appealing to ventures focused on innovation and sustainability in healthcare.
